Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients
- Autores
- Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto
- Año de publicación
- 2012
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd.
Fil: Dominguez, Raul Omar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Marschoff, Enrique Ricardo. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina
Fil: Gonzalez, Silvia Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Repetto, Marisa Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina
Fil: Serra, Jorge Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina - Materia
-
Alzheimer'S Disease
Cognitive Performance
Cognitive Tests
Type 2 Diabetes Mellitus - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/67436
Ver los metadatos del registro completo
id |
CONICETDig_b9e18b987b5d2c8b728be32a944f7aaf |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/67436 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patientsDominguez, Raul OmarMarschoff, Enrique RicardoGonzalez, Silvia EstelaRepetto, Marisa GabrielaSerra, Jorge AlbertoAlzheimer'S DiseaseCognitive PerformanceCognitive TestsType 2 Diabetes Mellitushttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd.Fil: Dominguez, Raul Omar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Marschoff, Enrique Ricardo. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Gonzalez, Silvia Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Repetto, Marisa Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; ArgentinaFil: Serra, Jorge Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; ArgentinaElsevier Ireland2012-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/67436Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto; Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients; Elsevier Ireland; Diabetes Research and Clinical Practice; 98; 1; 10-2012; 68-740168-8227CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.diabres.2012.05.013info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0168822712001763info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:57:07Zoai:ri.conicet.gov.ar:11336/67436instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:57:08.283CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients |
title |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients |
spellingShingle |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients Dominguez, Raul Omar Alzheimer'S Disease Cognitive Performance Cognitive Tests Type 2 Diabetes Mellitus |
title_short |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients |
title_full |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients |
title_fullStr |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients |
title_full_unstemmed |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients |
title_sort |
Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients |
dc.creator.none.fl_str_mv |
Dominguez, Raul Omar Marschoff, Enrique Ricardo Gonzalez, Silvia Estela Repetto, Marisa Gabriela Serra, Jorge Alberto |
author |
Dominguez, Raul Omar |
author_facet |
Dominguez, Raul Omar Marschoff, Enrique Ricardo Gonzalez, Silvia Estela Repetto, Marisa Gabriela Serra, Jorge Alberto |
author_role |
author |
author2 |
Marschoff, Enrique Ricardo Gonzalez, Silvia Estela Repetto, Marisa Gabriela Serra, Jorge Alberto |
author2_role |
author author author author |
dc.subject.none.fl_str_mv |
Alzheimer'S Disease Cognitive Performance Cognitive Tests Type 2 Diabetes Mellitus |
topic |
Alzheimer'S Disease Cognitive Performance Cognitive Tests Type 2 Diabetes Mellitus |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd. Fil: Dominguez, Raul Omar. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina Fil: Marschoff, Enrique Ricardo. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina Fil: Gonzalez, Silvia Estela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina Fil: Repetto, Marisa Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina Fil: Serra, Jorge Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina |
description |
Aim: To evaluate the cognitive performance of a homogeneous population of Alzheimer's disease (AD), non-demented Type 2 Diabetes Mellitus (DIAB), demented with concomitant diseases (AD+DIAB) and healthy control subjects. AD is a progressive dementia disorder characterized clinically by impairment of memory, cognition and behavior. Recently, a major research interest in AD has been placed on early evaluation. Diabetes is one of the clinical conditions that represent the greatest risk of developing oxidative stress and dementia. Glucose overload, leading to the development of impaired-induced insulin secretion in DIAB and has been suggested to slow or deter AD pathogenesis. Methods: The degree of cognitive impairment was determined on the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) and the Folstein's Mini Mental State Examination (MMSE); the severity of dementia was quantified applying the Clinical Dementia Rating (CDR) test; the Hamilton test was employed to evaluate depressive conditions; the final population studied was 101 subjects. Results: The cognitive deterioration is statistically significantly lower (p<0.05) in AD+DIAB patients as compared with AD patients. Conclusions: In this longitudinal study the superimposed diabetic condition was associated with a lower rate of cognitive decline, while diabetic non-demented patients and controls present normal scores. © 2012 Elsevier Ireland Ltd. |
publishDate |
2012 |
dc.date.none.fl_str_mv |
2012-10 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/67436 Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto; Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients; Elsevier Ireland; Diabetes Research and Clinical Practice; 98; 1; 10-2012; 68-74 0168-8227 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/67436 |
identifier_str_mv |
Dominguez, Raul Omar; Marschoff, Enrique Ricardo; Gonzalez, Silvia Estela; Repetto, Marisa Gabriela; Serra, Jorge Alberto; Type 2 diabetes and/or its treatment leads to less cognitive impairment in Alzheimer's disease patients; Elsevier Ireland; Diabetes Research and Clinical Practice; 98; 1; 10-2012; 68-74 0168-8227 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.diabres.2012.05.013 info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S0168822712001763 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier Ireland |
publisher.none.fl_str_mv |
Elsevier Ireland |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269442476605440 |
score |
13.13397 |